Table 5 Multivariate Cox proportional hazards regression for progression free (PFS) and overall survival (OS) in a model including post-treatment laboratory analyses after one cycle of docetaxel (q1) with either continuous or categorical CTC-counts
| Â | PFS | OS | |||||
|---|---|---|---|---|---|---|---|
CTC-assessment | Values in model | Hazard ratio | 95Â % CI | p= | Hazard ratio | 95Â % CI | p= |
Continuous CTC-values | CTC-value Continuous | 1.02 | 0.99-1.05 | 0.14 | 1.02 | 1.01-1.04 | 0.04 |
PSA-value ≥30 % decline | 1.8 | 0.6-5.6 | 0.3 | 2.6 | 0.9-7.78 | 0.09 | |
Lactate dehydrogenase ≤ ULN vs. >ULN | 1.2 | 0.2-10.2 | 0.8 | 0.7 | 0.1-3.4 | 0.65 | |
Alkaline phosphatase ≤ ULN vs. >ULN | 3.2 | 0.95-10.99 | 0.06 | 3.4 | 1.1-10.3 | 0.03 | |
Hemoglobin < LLN vs. ≥LLN | 2.7 | 0.3-28.4 | 0.4 | 1.7 | 0.2-17.0 | 0.63 | |
Categorical CTC-counts | CTC-count <5 CTCs vs. ≥5 CTCs | 3.9 | 1.1-13.8 | 0.04 | 4.9 | 1.6-15.7 | 0.007 |
PSA-value ≥30 % decline | 1.8 | 0.6-5.3 | 0.3 | 3.0 | 1.03-8.8 | 0.04 | |
Lactate ehydrogenase ≤ ULN vs. >ULN | 1.5 | 0.2-11.8 | 0.7 | 0.8 | 0.2-3.9 | 0.84 | |
Alkaline phosphatase ≤ ULN vs. >ULN | 1.9 | 0.5-7.4 | 0.4 | 2.0 | 0.6-6.5 | 0.27 | |
Hemoglobin < LLN vs. ≥LLN | 3.3 | 0.3-34.3 | 0.3 | 2.2 | 0.2-21.0 | 0.5 | |